Company Overview of Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. researches and develops drugs for the treatment of debilitating neurogenic disorders. It develops P2X3, a purinergic receptor that plays a role in the sensitization of nerves; AF-219, a selective P2X3 antagonist for the treatment of pathologic cough; and P2X3 antagonist that blocks P2X3 in the carotid body. It offers programs in the areas of respiratory diseases, resistant hypertension, P2X3 biology, cardiovascular diseases, and chronic pain and other indications; and clinical trials. The company was founded in 2009 and is based in San Mateo, California. As of July 26, 2016, Afferent Pharmaceuticals, Inc. operates as a subsidiary of Merck & Co., Inc.
2929 Campus Drive
San Mateo, CA 94403
Founded in 2009
Key Executives for Afferent Pharmaceuticals, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Afferent Pharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.